High-dose probiotics for the treatment of active pouchitis

被引:161
作者
Gionchetti, Paolo [1 ]
Rizzello, Fernando [1 ]
Morselli, Claudia [1 ]
Poggioli, Gilberto [2 ]
Tambasco, Rosi [1 ]
Calabrese, Carlo [1 ]
Brigidi, Patrizia [3 ]
Vitali, Beatrice [3 ]
Straforini, Giulia [1 ]
Campieri, Massimo [1 ]
机构
[1] Univ Bologna, Policlin S Orsola, Dept Int Med & Gastroenterool, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Clin Surg, Bologna, Italy
[3] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
关键词
ulcerative colitis; pouchitis; probiotics;
D O I
10.1007/s10350-007-9068-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: Pouchitis is the major long-term complication after ileal-pouch anal anastomosis for ulcerative colitis. Broad-spectrum antibiotics are the mainstay of treatment in this condition. Recently, we have shown the efficacy of a highly concentrated probiotic preparation (VSL#3, 900 billions/sachet lyophilized viable bacteria) in preventing relapses of chronic pouchitis and in preventing pouchitis onset. This study was designed to evaluate the efficacy of high-dose VSL#3 in the treatment of mildly active pouchitis. METHODS: Twenty-three consecutive patients with mild pouchitis, defined as a score of between 7 and 12 in the Pouchitis Disease Activity Index, which includes clinical, endoscopic, and histological criteria, were treated with VSL#3, 2 sachets b.i.d. (3600 billion bacteria/day) for four weeks. Symptomatic, endoscopic, and histologic evaluations were undertaken before and after treatment according to Pouchitis Disease Activity Index. Remission was defined as a combination of a Pouchitis Disease Activity Index clinical score of <= 2, endoscopic score of <= 1, and total Pouchitis Disease Activity Index score of <= 4. Patients in remission after treatment were treated with VSL#3, 1 sachet b.i.d. (1800 billion bacteria), as maintenance treatment for six months. The quality of life was assessed with the Inflammatory Bowel Disease Questionnaire. RESULTS: Sixteen of 23 patients (69 percent) were in remission after treatment. The median total Pouchitis Disease Activity Index scores before and after therapy were 10 (range, 9-12) and 4 (range, 2-11), respectively (P < 0.01). The median Inflammatory Bowel Disease Questionnaire score also significantly improved from 110 (range, 90-140) to 200 (range, 95-220; P < 0.001). All 16 patients who went into remission maintained remission during maintenance treatment. Only one patient experienced a transient bloating at the beginning of treatment. CONCLUSIONS: High doses of the probiotic VSL#3 are effective in the treatment of mild pouchitis. Further controlled studies are warranted.
引用
收藏
页码:2075 / 2082
页数:8
相关论文
共 41 条
[1]   VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis [J].
Bibiloni, R ;
Fedorak, RN ;
Tannock, GW ;
Madsen, KL ;
Gionchetti, P ;
Campieri, M ;
De Simone, C ;
Sartor, RB .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (07) :1539-1546
[2]   Specific detection of Bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction [J].
Brigidi, P ;
Vitali, B ;
Swennen, E ;
Altomare, L ;
Rossi, M ;
Matteuzzi, D .
SYSTEMATIC AND APPLIED MICROBIOLOGY, 2000, 23 (03) :391-399
[3]   Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative? [J].
Campieri, M ;
Gionchetti, P .
GASTROENTEROLOGY, 1999, 116 (05) :1246-1249
[4]   Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii ssp bulgaricus, Lactobacillus acidophilus, and bifidobacteria [J].
Dave, RI ;
Shah, NP .
JOURNAL OF DAIRY SCIENCE, 1996, 79 (09) :1529-1536
[5]   THE EFFECT OF EXOGENOUS ADMINISTRATION OF LACTOBACILLUS-REUTERI R2LC AND OAT FIBER ON ACETIC ACID-INDUCED COLITIS IN THE RAT [J].
FABIA, R ;
ARRAJAB, A ;
JOHANSSON, ML ;
WILLEN, R ;
ANDERSSON, R ;
MOLIN, G ;
BENGMARK, S .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (02) :155-162
[6]   Long-term functional outcome and quality of life after stapled restorative proctocolectomy [J].
Fazio, VW ;
O'Riordain, MG ;
Lavery, IC ;
Church, JM ;
Lau, P ;
Strong, SA ;
Hull, T .
ANNALS OF SURGERY, 1999, 230 (04) :575-584
[7]   Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Brigidi, P ;
Matteuzzi, D ;
Bazzocchi, G ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2000, 119 (02) :305-309
[8]   Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Ugolini, F ;
Rossi, M ;
Brigidi, P ;
Johansson, R ;
Ferrieri, A ;
Poggioli, G ;
Campieri, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) :713-718
[9]   Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Helwig, U ;
Venturi, A ;
Lammers, KM ;
Brigidi, P ;
Vitali, B ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2003, 124 (05) :1202-1209
[10]   A NEW MEASURE OF HEALTH-STATUS FOR CLINICAL-TRIALS IN INFLAMMATORY BOWEL-DISEASE [J].
GUYATT, G ;
MITCHELL, A ;
IRVINE, EJ ;
SINGER, J ;
WILLIAMS, N ;
GOODACRE, R ;
TOMPKINS, C .
GASTROENTEROLOGY, 1989, 96 (03) :804-810